Moreover, our study indicated that the serum levels of IGF-1 and IGFBP-3 were within the normal range in newly diagnosed ADHD patients, and that atomoxetine will not affect the serum concentration of growth parameters in the short-term. This evidence concerns the gene IGF1 and attention deficit-hyperactivity disorder.